Bristol-Myers Squibb

Bristol-Myers Squibb and Vedanta Biosciences to Evaluate Opdivo and VE800 in Patients with Advanced or Metastatic Cancers
Bristol-Myers Squibb and Vedanta Biosciences to Evaluate Opdivo and VE800 in Patients with Advanced or Metastatic Cancers
CP WIre
Bristol-Myers Squibb
Vedanta Biosciences
Opdivo
VE800
micro
Flag link:
Bristol-Myers Squibb and Vedanta Biosciences to Evaluate Opdivo and VE800 in Patients with Advanced or Metastatic Cancers
Bristol-Myers Squibb
Vedanta Biosciences
Opdivo
VE800
microbiome
Flag link:
CEO of Chapel Hill firm talks 2 new partnerships with big pharma
CEO of Chapel Hill firm talks 2 new partnerships with big pharma
Bizjournals
Target PharmaSolutions
Gilead Sciences
Bristol-Myers Squibb
hepatitis B
NASH
Flag link:
BMS' second small-cell trial flop endangers Opdivo lung cancer approval: analyst
BMS' second small-cell trial flop endangers Opdivo lung cancer approval: analyst
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
extensive-stage small cell lung cancer
Flag link:
Bristol-Myers Drops After Lung-Cancer Drug Study Fails
Bristol-Myers Drops After Lung-Cancer Drug Study Fails
TheStreet.com
Bristol-Myers Squibb
Opdivo
Yeroy
extensive-stage small cell lung cancer
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Bristol-Myers Squibb laying off 69 employees in Florida in push to 'focus resources'
Bristol-Myers Squibb laying off 69 employees in Florida in push to 'focus resources'
Fierce Pharma
Bristol-Myers Squibb
layoffs
Florida
Flag link:
How Bristol-Myers Squibb Company Fell $18.8 Billion in October
How Bristol-Myers Squibb Company Fell $18.8 Billion in October
Motley Fool
Bristol-Myers Squibb
Opdivo
Flag link:
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
FDA
Multiple Myeloma
Celgene
Pomalyst
Flag link:
Bristol-Myers lays off the last 63 staffers at ZymoGenetics, shutters Seattle operations
Bristol-Myers lays off the last 63 staffers at ZymoGenetics, shutters Seattle operations
Endpoints
Bristol-Myers Squibb
layoffs
ZymoGenetics
Flag link:
Pharma Giants Merck, Bristol Diverge On Earnings Beat As Sales Lag
Pharma Giants Merck, Bristol Diverge On Earnings Beat As Sales Lag
Investors.com
Merck
Bristol-Myers Squibb
earnings
Flag link:
Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug
Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug
Marketwatch
Bristol-Myers Squibb
clinical trials
Opdivo
Yervoy
FDA
Flag link:
Pfizer preps for BMS showdown with Bavencio kidney cancer combo data
Pfizer preps for BMS showdown with Bavencio kidney cancer combo data
Fierce Pharma
Pfizer
Bristol-Myers Squibb
kidney cancer
Bavencio
Flag link:
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Flag link:
FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC
FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC
BioCentury
Bristol-Myers Squibb
Opdivo
FDA
EMA
Yervoy
non-small cell lung cancer
Flag link:
Real threat to Opdivo’s small-cell chances will come from elsewhere
Real threat to Opdivo’s small-cell chances will come from elsewhere
EP Vantage
Bristol-Myers Squibb
Opdivo
Small-Cell Lung Cancer
FDA
Tecentriq
Roche
Flag link:
Stada and Mylan targeting Bristol-Myers Squibb’s Upsa (€1bn)
Stada and Mylan targeting Bristol-Myers Squibb’s Upsa (€1bn)
GoinPharma
Stada
OTC
Upsa
Bristol-Myers Squibb
Flag link:
Bristol-Myers Squibb's Opdivo Misses Primary Endpoint in Ph III Study in Small Cell Lung Cancer
Bristol-Myers Squibb's Opdivo Misses Primary Endpoint in Ph III Study in Small Cell Lung Cancer
CP Wire
Bristol-Myers Squibb
Opdivo
Small-Cell Lung Cancer
clinical trials
Flag link:
Bristol-Myers Squibb's Opdivo Misses Primary Endpoint in Ph III Study in Small Cell Lung Cancer
Bristol-Myers Squibb
Opdivo
Small-Cell Lung Cancer
Flag link:
Bristol-Myers to invest in Compugen, collaborate in clinical trials
Bristol-Myers to invest in Compugen, collaborate in clinical trials
Yahoo/Reuters
Bristol-Myers Squibb
CompuGen
clinical trials
solid tumors
COM701
Opdivo
Flag link:

Pages